Regorafenib

STIVARGA

Open Regorafenib in the interactive console ↗

Pronunciation: re-goe-RAF-e-nib (sti-VAR-ga)

Regorafenib ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Regorafenib ballicule

What it isOral RET/VEGFR multikinase inhibitor; refractory colorectal cancer, GIST, and hepatocellular carcinoma.

Why this oneIts clinical niche spans three otherwise distinct gastrointestinal cancers after standard options fail.

What limits itHand-foot skin reaction is often dose-limiting; hepatotoxicity, hypertension, and bleeding require monitoring.

Regorafenib molecular structure (skeletal formula) — Molecular structure: Regorafenib

Regorafenib prescription history

Animated chart of estimated U.S. prescriptions per year, Tyrosine kinase inhibitors (2001–2026). Regorafenib enters in 2012 (estimated).

FDA-approved for

metastatic colorectal cancer (2012)
GIST, hepatocellular carcinoma

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4

Overdose danger2 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk3 / 4

Legacy pregnancy categoryD

Defining liabilityMyelosuppression and agent-specific hepatic, cardiac, pulmonary, neurologic or reproductive toxicity require oncology monitoring.

FDA label

Read the full label on DailyMed ↗

BOXED WARNING Hepatotoxicity — severe and sometimes fatal; monitor hepatic function before and during treatment; interrupt/reduce/discontinue for hepatotoxicity

FDA dosing	Population	Start	Target	Max
Metastatic colorectal cancer, GIST, hepatocellular carcinoma	Adults	160 mg QD, days 1-21 of each 28-day cycle	160 mg QD (days 1-21)	160 mg/day

Renal No adjustment needed

Hepatic No adjustment for mild-moderate impairment; not recommended in severe (bilirubin >3x ULN)

21 days on, 7 days off (28-day cycle)

Instructions

Take after a low-fat meal (<600 cal, <30% fat)
Swallow tablets whole with water at the same time daily
Do not take two doses on the same day for a missed dose
Reduce dose in 40 mg increments; lowest dose 80 mg/day
Withhold >=2 wks before elective surgery

Available strengths

tab 40 mg

Cautions

Hepatotoxicity — monitor LFTs
Infections
Hemorrhage (discontinue if severe)
GI perforation/fistula (discontinue)
Dermatologic toxicity / hand-foot skin reaction
Hypertension
Cardiac ischemia/infarction
Reversible posterior leukoencephalopathy syndrome (RPLS)
Impaired wound healing
Embryo-fetal toxicity

Adverse reactions

Pain
Hand-foot skin reaction
Asthenia/fatigue
Diarrhea
Decreased appetite
Hypertension
Infection
Dysphonia
Hyperbilirubinemia
Fever
Mucositis
Weight loss
Rash
Nausea

Pregnancy Can cause fetal harm — embryolethal and teratogenic in animals below human exposures

Lactation Do not breastfeed during treatment and for 2 wks after final dose

Cost

Regorafenib (STIVARGA)

Strength		#/mo	generic $/mo	CostPlus
40 mg	tab	30 qd		not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Regorafenib is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2025

Open Regorafenib in the interactive console ↗

Self-check

Regorafenib: At what treatment stage is its GI-cancer niche?
After standard options fail.
Regorafenib: Which skin reaction is often dose-limiting?
Hand-foot skin reaction.